SCHEMBL4293397

SCHEMBL4293397

O=C(O)CCC(=O)OC[C@@H](O)CO

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.58
KDM4E B2RXH2 1/20 0.58
DUSP3 P51452 1/20 0.58
MEN1 O00255 1/20 0.58
KMT2A Q03164 1/20 0.58
DGKA P23743 1/20 0.49
FAAH O00519 4/20 0.46
EGLN1 Q9GZT9 2/20 0.38
KDM6B O15054 1/20 0.38
KDM5C P41229 1/20 0.38
PHF8 Q9UPP1 1/20 0.38
KDM2A Q9Y2K7 1/20 0.38
ALKBH5 Q6P6C2 1/20 0.38
SUCNR1 Q9BXA5 1/20 0.38
CNR2 P34972 3/20 0.36
LPAR6 P43657 1/20 0.36
LPAR1 Q92633 1/20 0.36
LPAR4 Q99677 1/20 0.36
LPAR5 Q9H1C0 1/20 0.36
LPAR2 Q9HBW0 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Succinic Acid SCHEMBL28660950 1.00 LMNA (0.58) LMNAKDM4EDUSP3MEN1KMT2A
SCHEMBL236696 1.00 LMNA (0.58) LMNAKDM4EDUSP3MEN1KMT2A
Ammonia Solution, Strong SCHEMBL18155124 0.98 LMNA (0.56) LMNAKDM4EDUSP3MEN1KMT2A
SCHEMBL27544055 0.94 LMNA (0.53) LMNAKDM4EDUSP3MEN1KMT2A
Butanedione SCHEMBL27698634 0.93 LMNA (0.56) LMNAKDM4EDUSP3MEN1KMT2A
SCHEMBL26008133 0.93 LMNA (0.51) LMNAKDM4EDUSP3MEN1KMT2A
SCHEMBL236697 0.91 LMNA (0.66) LMNAKDM4EDUSP3MEN1KMT2A
SCHEMBL27946735 0.91 LMNA (0.54) LMNAKDM4EDUSP3MEN1KMT2A
SCHEMBL270754 0.88 LMNA (0.69) LMNAKDM4EDUSP3MEN1KMT2A
SCHEMBL27457920 0.88 KDM4E (0.64) LMNAKDM4EDUSP3MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090220587-A1 Liposomal drug delivery constructs targeted by lipid-conjugated peptide ligands UNITED STATE ARMY (US) 2009-09-03 US claimed
US-20090220587-A1 Liposomal drug delivery constructs targeted by lipid-conjugated peptide ligands UNITED STATE ARMY (US) 2009-09-03 US disclosed
EP-1383480-A4 LIPID-COMPRISING DRUG DELIVERY COMPLEXES AND METHODS FOR THEIR PRODUCTION TARGETED GENETICS CORP (US) 2006-05-24 EP disclosed
EP-1383480-A2 LIPID-COMPRISING DRUG DELIVERY COMPLEXES AND METHODS FOR THEIR PRODUCTION TARGETED GENETICS CORPORATION (US) 2004-01-28 EP disclosed
WO-2002088318-A2 LIPID-COMPRISING DRUG DELIVERY COMPLEXES AND METHODS FOR THEIR PRODUCTION TARGETED GENETICS CORPORATION (US) 2002-11-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090220587-A1 Liposomal drug delivery constructs targeted by lipid-conjugated peptide ligands LDLR, LAMP2, LAMP1 LMNA 1678/4885KDM4E 4023/4885DUSP3 3781/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.